Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals (GPSA) has concluded a Phase I trial evaluating GRC 15300 as a treatment for pain.
Subscribe to our email newsletter
A subsidiary of Glenmark Pharmaceuticals Limited India (GPL), GPSA’s GRC 15300 is an inhibitor of the TRPV3 and has demonstrated significant pharmacokinetic profile in the trial.
The results of the trial also showed that the drug was well tolerated.
The company intends to start clinical proof of concept studies in patients suffering from neuropathic pain in near future.
GPL chairman and MD Glenn Saldanha said they are looking forward to continued development on the program.